25/07/23 -"Borealis/Borouge merge A catalyst or a headache for OMV?"
25/07/23 -"Borealis/Borouge merge A catalyst or a headache for OMV?"
The announcement of negotiations between OMV and ADNOC on a merger of Borealis and Borouge has rekindled interest in the Austrian company and the European chemicals sector. In its strategic vision, OMV committed to becoming an integrated chemicals company in 2022, right after the sector had a good run on margins. Under the current prevailing environment, what could OMV do in terms of simplification, integration and diversification of operations/products to create more value? Could a merger of Borealis and Borouge with ADNOC provide the much-needed catalyst for OMV or will it be tedious and costly job for the company? What value will it bring for shareholders?
AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.
| Corporate broking | NO |
| Trading in corporate shares | NO |
| Analyst ownership | NO |
| Advising of corporate (strategy, marketing, debt, etc) | NO |
| Research paid for by corporate | NO |
| Provision of corporate access paid for by corporate | NO |
| Link between and a banking entity | NO |
| Brokerage activity at AlphaValue | NO |